Patent SG-11201909353V-A (SG)
Title: Hbv vaccine
Inventor: BARNES ELEANOR
IPC: A61K39/00
Filed: 2018-04-10
Abstract: HBVCPmutS I CMV promote Linker } FA Non-HBV amino acids Pre F2 PreS Core Polymerase (Pmut) PreS1 Surface C A 2 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) WIP0 I PCT IiiimmounnotiolomonoinolommovoimIE (10) International Publication Number WO 2018/189522 Al (51) International Patent Classification: A61K 39/29 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/GB2018/050948 (22) International Filing Date: 10 April 2018 (10.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1705765.4 10 April 2017 (10.04.2017) GB (71) Applicant: OXFORD UNIVERSITY INNOVATION LTD. [GB/GB]; Buxton Court, 3 West Way, Oxford Ox- fordshire OX2 OJB (GB). (72) Inventors: BARNES, Eleanor; c/o Oxford University In- novation Limited, Buxton Court, 3 West Way, Oxford Ox- fordshire OX2 OJB (GB). CHINNAKANNAN, Senthil; c/ o Oxford University Innovation Limited, Buxton Court, 3 West Way, Oxford Oxfordshire OX2 OJB (GB). (74) Agent: BARKER BRETTELL LLP; Medina Chambers, Town Quay, Southampton Hampshire S014 2AQ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: HBV VACCINE Linker Figure 4A N I / 4/ Cleavage sites (57) : The invention relates to a multi-HBV immunogen viral vector vaccine comprising: a viral vector comprising an im- munogen expression cassette, wherein the expression of a protein encoded by the expression cassette is arranged to be driven by a pro- moter, wherein the immunogen expression cassette encodes: a) HBV Core; b) a modified HBV polymerase (P mut ), wherein the modi- fication is a mutation to wild-type HBV polymerase to substantially remove polymerase function; c) HBV surface antigen (HbsAg); and d) an intergenic sequence that is arranged to cause expression of at least the HBV surface antigen (HbsAg) as a separate protein from the HBV core and the modified HBV polymerase (P ), wherein the intergenic sequence is downstream (3') of the sequences mut encoding the HBV core and the modified HBV polymerase (P mut ) and upstream (5') of the sequence encoding the HBV surface antigen (HbsAg); and related compositions, vaccination methods and methods of treatment or prophylaxis of HBV infection.